Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 0.48 |
| ▸ | DRD2 | P14416 | 6/20 | 0.46 |
| ▸ | NCF1 | P14598 | 10/20 | 0.41 |
| ▸ | CYBB | P04839 | 1/20 | 0.40 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23267580 | 1.00 | GBA1 (0.48) | GBA1DRD2NCF1CYBBNOX5 | |
| SCHEMBL23267576 | 1.00 | GBA1 (0.48) | GBA1DRD2NCF1CYBBNOX5 | |
| SCHEMBL12033359 | 0.98 | GBA1 (0.49) | GBA1DRD2NCF1CYBBNOX5 | |
| SCHEMBL25921415 | 0.90 | DRD2 (0.46) | GBA1DRD2NCF1CYBBNOX5 | |
| SCHEMBL23268012 | 0.89 | DGAT1 (0.42) | GBA1DRD2NCF1CYBBNOX5 | |
| SCHEMBL12033014 | 0.89 | DGAT1 (0.42) | GBA1DRD2NCF1CYBBNOX5 | |
| SCHEMBL19589313 | 0.89 | DGAT1 (0.42) | GBA1DRD2NCF1CYBBNOX5 | |
| SCHEMBL24894085 | 0.89 | DRD2 (0.53) | GBA1DRD2NCF1CYBBNOX5 | |
| SCHEMBL23267819 | 0.89 | DGAT1 (0.42) | GBA1DRD2NCF1CYBBNOX5 | |
| SCHEMBL19576084 | 0.87 | GBA1 (0.49) | GBA1DRD2NCF1CYBBNOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023114746-A1 | FUNCTIONALIZED N-ACETYLGALACTOSAMINE ANALOGS | HONGENE BIOTECH CORPORATION (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20170166562-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | AUSPEX PHARMACEUTICALS INC (US) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166562-A1 | BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 | SLC18A2, SLC6A2, SLC18A1 | GBA1 759/4885DRD2 399/4885NCF1 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.